Bright Minds Biosciences Inc.
DRUG · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $55 | $0 | $0 | $0 |
| Gross Profit | -$55 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $7,959 | $1,180 | $5,000 | $12,181 |
| G&A Expenses | $2,136 | $1,395 | $2,080 | $1,999 |
| SG&A Expenses | $2,565 | $1,437 | $2,200 | $2,551 |
| Sales & Mktg Exp. | $430 | $42 | $119 | $552 |
| Other Operating Expenses | -$598 | $0 | $0 | -$0 |
| Operating Expenses | $9,926 | $2,617 | $7,200 | $14,732 |
| Operating Income | -$13,938 | -$2,617 | -$7,200 | -$14,732 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,708 | -$185 | -$172 | -$233 |
| Pre-Tax Income | -$12,229 | -$2,802 | -$7,372 | -$14,965 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12,229 | -$2,802 | -$7,372 | -$14,965 |
| % Margin | – | – | – | – |
| EPS | -1.28 | -0.65 | -1.98 | -6.15 |
| % Growth | -96.9% | 67.2% | 67.8% | – |
| EPS Diluted | -1.28 | -0.65 | -1.98 | -6.15 |
| Weighted Avg Shares Out | 6,878 | 4,310 | 3,719 | 2,470 |
| Weighted Avg Shares Out Dil | 6,878 | 4,310 | 3,720 | 2,470 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,091 | $21 | $0 | $0 |
| Interest Expense | $26 | $0 | $0 | $0 |
| Depreciation & Amortization | $55 | $2,617 | $72 | $6 |
| EBITDA | -$8,700 | $0 | -$7,280 | -$14,726 |
| % Margin | – | – | – | – |